Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:4450 |
Name | renal cell carcinoma |
Definition | A renal carcinoma that has_material_basis_in the lining of the proximal convoluted renal tubule of the kidney. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer urinary system cancer kidney cancer renal carcinoma renal cell carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
VHL negative | STF-62247 | renal cell carcinoma | sensitive | detail... |
CDKN2A loss | Palbociclib | renal cell carcinoma | sensitive | detail... |
VHL mutant | Sunitinib | renal cell carcinoma | predicted - sensitive | detail... |
VHL loss | Bevacizumab | renal cell carcinoma | sensitive | detail... |
VHL loss | ELR510444 | renal cell carcinoma | sensitive | detail... |
VHL mutant | Everolimus | renal cell carcinoma | sensitive | detail... |
BRAF V600E | Vemurafenib | renal cell carcinoma | predicted - sensitive | detail... |
PTEN dec exp | Apitolisib | renal cell carcinoma | no benefit | detail... |
PIK3CA act mut PTEN dec exp | Apitolisib | renal cell carcinoma | no benefit | detail... |
VHL inact mut | Apitolisib | renal cell carcinoma | no benefit | detail... |
PBRM1 inact mut | Apitolisib | renal cell carcinoma | no benefit | detail... |
PTEN dec exp | Everolimus | renal cell carcinoma | no benefit | detail... |
PIK3CA act mut PTEN dec exp | Everolimus | renal cell carcinoma | no benefit | detail... |
VHL inact mut | Everolimus | renal cell carcinoma | predicted - sensitive | detail... |
PBRM1 inact mut | Everolimus | renal cell carcinoma | no benefit | detail... |
TSC1 inact mut | Everolimus | renal cell carcinoma | predicted - sensitive | detail... |
TSC2 inact mut | Everolimus | renal cell carcinoma | predicted - sensitive | detail... |
TSC1 inact mut | Temsirolimus | renal cell carcinoma | predicted - sensitive | detail... |
TSC2 inact mut | Temsirolimus | renal cell carcinoma | predicted - sensitive | detail... |
FGFR1 over exp | Sorafenib | renal cell carcinoma | not applicable | detail... |
VHL del | Regorafenib | renal cell carcinoma | predicted - sensitive | detail... |
VHL inact mut | Alpha 2 Interferon + Bevacizumab | renal cell carcinoma | predicted - sensitive | detail... |
VHL loss | BPTES | renal cell carcinoma | sensitive | detail... |
VHL loss | Telaglenastat | renal cell carcinoma | sensitive | detail... |
VHL loss | Olaparib + Telaglenastat | renal cell carcinoma | sensitive | detail... |
VHL loss | BPTES + Olaparib | renal cell carcinoma | sensitive | detail... |
VHL mutant | Unspecified VEGFR inhibitor | renal cell carcinoma | no benefit | detail... |
TSC1 mutant | Everolimus | renal cell carcinoma | conflicting | detail... |
TSC2 mutant | Everolimus | renal cell carcinoma | conflicting | detail... |
PTEN loss | Everolimus | renal cell carcinoma | predicted - sensitive | detail... |
PTEN negative | Temsirolimus | renal cell carcinoma | predicted - sensitive | detail... |
PTEN negative | Everolimus | renal cell carcinoma | predicted - sensitive | detail... |
TSC1 mutant | Temsirolimus | renal cell carcinoma | predicted - sensitive | detail... |
TSC2 mutant | Temsirolimus | renal cell carcinoma | predicted - sensitive | detail... |
VHL inact mut | Belzutifan | renal cell carcinoma | sensitive | detail... |
CDKN2A inact mut | unspecified immune checkpoint inhibitor | renal cell carcinoma | not predictive | detail... |
CDKN2A del | unspecified immune checkpoint inhibitor | renal cell carcinoma | not predictive | detail... |
VHL inact mut | Pazopanib | renal cell carcinoma | sensitive | detail... |
EML4 - ALK | Alectinib | renal cell carcinoma | predicted - sensitive | detail... |
TP53 wild-type VHL inact mut | M8891 + Sunitinib | renal cell carcinoma | sensitive | detail... |
TP53 wild-type VHL inact mut | Cabozantinib + M8891 | renal cell carcinoma | sensitive | detail... |
TP53 wild-type VHL inact mut | Axitinib + M8891 | renal cell carcinoma | sensitive | detail... |
ALK fusion | Alectinib | renal cell carcinoma | predicted - sensitive | detail... |
ALK rearrange | Crizotinib | renal cell carcinoma | predicted - sensitive | detail... |
TP53 wild-type | BI 907828 | renal cell carcinoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00003553 | Phase II | Cyclophosphamide + Fludarabine Cyclosporine Mycophenolate mofetil Methotrexate | Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer | Completed | USA | 0 |
NCT00184015 | Phase Ib/II | Bevacizumab + Bortezomib | Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC) | Unknown status | USA | 0 |
NCT00301990 | Phase II | Aldesleukin + Bevacizumab | Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer | Unknown status | USA | 0 |
NCT00717587 | Phase II | Sunitinib Girentuximab Motexafin gadolinium | Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer | Unknown status | USA | 0 |
NCT00720785 | Phase I | Bortezomib | Natural Killer Cells and Bortezomib to Treat Cancer | Completed | USA | 0 |
NCT00828919 | Phase I | Axitinib | Continuing Access To AG- 013736 (A406) For Patients Previously Receiving AG 013736 In Clinical Trials | Completed | USA | ITA | HUN | GBR | FRA | DEU | CZE | 4 |
NCT00923130 | Phase II | Bevacizumab + Ixabepilone | Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer | Completed | USA | 0 |
NCT00923845 | Phase II | Sirolimus Cyclophosphamide + Pentostatin | Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer | Completed | USA | 0 |
NCT01014065 | Phase II | Sunitinib | A Prospective Study of Acute Cardiovascular Effects of First-line Sunitinib in Metastatic Renal Cell Carcinoma Patients (SUnitinib Prospective CardiovasculaR Effect) | Completed | CAN | 0 |
NCT01026337 | Phase 0 | Sunitinib | Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer | Completed | USA | 0 |
NCT01120249 | Phase III | Everolimus | S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery (S0931) | Active, not recruiting | USA | 1 |
NCT01164228 | Phase II | Sunitinib Gemcitabine | Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery | Completed | USA | 0 |
NCT01221506 | Phase I | Pazopanib | Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC) | Completed | USA | 0 |
NCT01283048 | Phase I | Bevacizumab + Buparlisib | Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma | Completed | USA | 0 |
NCT01307267 | Phase I | Rituximab + Utomilumab Utomilumab | A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | Completed | USA | ITA | FRA | AUS | 1 |
NCT01331135 | Phase I | Sirolimus | Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors | Completed | USA | 0 |
NCT01361113 | Phase II | Pazopanib | Neoadjuvant Pazopanib in Renal Cell Carcinoma | Completed | USA | 0 |
NCT01370109 | Phase I | Sunitinib | Cardiovascular Effects of Sunitinib Therapy (CREST) | Completed | USA | 0 |
NCT01391143 | Phase I | MGA271 | Safety Study of MGA271 in Refractory Cancer | Completed | USA | 0 |
NCT01399918 | Phase II | Bevacizumab + Everolimus | Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC) | Completed | USA | 0 |
NCT01480154 | Phase I | Hydroxychloroquine + MK2206 | Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer | Active, not recruiting | USA | 0 |
NCT01510119 | Phase Ib/II | Everolimus + Hydroxychloroquine | Autophagy Inhibition to Augment mTOR Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine in Patients With Previously Treated Renal Cell Carcinoma | Completed | USA | 0 |
NCT01517243 | Phase II | Temsirolimus Sunitinib | Phase II Study of Alternating Sunitinib and Temsirolimus | Completed | USA | 0 |
NCT01543763 | Phase I | Panobinostat + Pazopanib | Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors | Active, not recruiting | USA | 0 |
NCT01575548 | Phase III | Pazopanib | Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery | Active, not recruiting | USA | 0 |
NCT01582009 | Phase Ib/II | Everolimus + Panobinostat | Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate | Terminated | USA | 0 |
NCT01582672 | Phase III | Sunitinib | Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC) | Terminated | USA | ITA | ISR | HUN | GBR | ESP | CZE | CAN | 0 |
NCT01625936 | Phase I | Bevacizumab NLG207 | CRLX101 Plus Bevacizumab in Advanced RCC | Completed | USA | 0 |
NCT01649180 | Phase II | Axitinib | NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma (PrE0801) | Terminated | USA | 0 |
NCT01664182 | Phase II | Sunitinib + Trebananib Pazopanib + Trebananib Sorafenib + Trebananib Trebananib Bevacizumab + Trebananib | Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer | Completed | USA | 0 |
NCT01727336 | Phase II | Axitinib + Dalantercept Axitinib | Study of Dalantercept in Patients With Advanced Renal Cell Carcinoma | Terminated | USA | 0 |
NCT01730118 | Phase I | HER2 Vaccine | Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing | Completed | USA | 0 |
NCT01767636 | Phase II | Pazopanib | Pazopanib in Treating Patients With Metastatic Non-Clear Cell Kidney Cancer | Active, not recruiting | USA | 0 |
NCT01806064 | Phase I | Bevacizumab + Carotuximab | A Phase 1B Dose-escalation Study of TRC105 in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma | Terminated | USA | HUN | GBR | CZE | 0 |
NCT01835158 | Phase II | Cabozantinib Cabozantinib + Sunitinib | Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer | Completed | USA | 0 |
NCT01865747 | Phase III | Everolimus Cabozantinib | A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma | Completed | USA | TUR | SWE | SVK | POL | NLD | ITA | IRL | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BEL | AUT | AUS | ARG | 5 |
NCT01946789 | Phase I | Nogapendekin alfa inbakicept | A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT01984242 | Phase II | Atezolizumab Sunitinib Atezolizumab + Bevacizumab + Capecitabine | A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) as Monotherapy or in Combination With Avastin (Bevacizumab) Compared to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma | Completed | USA | ROU | POL | ITA | GBR | FRA | ESP | DEU | CZE | 0 |
NCT02009449 | Phase I | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin Nab-paclitaxel | A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02013804 | Phase I | MEDI0680 | A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies | Completed | USA | 0 |
NCT02014636 | Phase I | Pazopanib Pembrolizumab | Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC) | Completed | USA | GBR | 0 |
NCT02071862 | Phase I | Everolimus + Telaglenastat Erlotinib + Telaglenastat Docetaxel + Telaglenastat Telaglenastat Paclitaxel + Telaglenastat Cabozantinib + Telaglenastat | Study of the Glutaminase Inhibitor CB-839 in Solid Tumors | Completed | USA | 0 |
NCT02082210 | Phase Ib/II | Emibetuzumab + Ramucirumab | A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer | Completed | USA | 0 |
NCT02089334 | Phase Ib/II | Everolimus + RX-0201 Everolimus | Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer | Terminated | USA | 0 |
NCT02089685 | Phase Ib/II | Ipilimumab Peginterferon alfa-2b Pembrolizumab | Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) | Completed | 0 | |
NCT02122809 | Phase I | Chiauranib | Phase I Study of Chiauranib in Patients With Advanced Solid Tumors | Completed | 1 | |
NCT02133742 | Phase I | Axitinib + Pembrolizumab | A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer | Completed | USA | 0 |
NCT02164838 | Phase I | Axitinib | VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors | Completed | USA | CAN | 0 |
NCT02170389 | Phase I | AGS-003 | Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer | Terminated | USA | 0 |
NCT02174172 | Phase I | Atezolizumab + Bevacizumab + Peg-interferon alfa-2a Atezolizumab + Interferon alpha-2b Atezolizumab + Peg-interferon alfa-2a Atezolizumab + Ipilimumab Atezolizumab + Obinutuzumab | A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors | Completed | USA | NLD | 0 |
NCT02178722 | Phase Ib/II | Epacadostat + Pembrolizumab | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | Completed | USA | 0 |
NCT02187302 | Phase II | Bevacizumab + NLG207 | CRLX101 in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC) | Completed | USA | 1 |
NCT02212730 | Phase I | Pembrolizumab | A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031) | Terminated | 0 | |
NCT02231749 | Phase III | Ipilimumab + Nivolumab Sunitinib | Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) | Active, not recruiting | USA | TUR | SWE | POL | NLD | ITA | ISR | IRL | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 6 |
NCT02273752 | Phase II | Everolimus | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer | Terminated | USA | 0 |
NCT02298959 | Phase I | Aflibercept + Pembrolizumab | Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors | Active, not recruiting | USA | CAN | 0 |
NCT02404441 | Phase Ib/II | Spartalizumab | Phase I/II Study of PDR001 in Patients With Advanced Malignancies | Completed | USA | TUR | POL | NOR | NLD | LBN | ITA | HUN | FRA | ESP | DEU | CAN | 2 |
NCT02406521 | Phase I | Pazopanib Radium Ra 223 dichloride Sorafenib | Exploratory Study of Radium-223 and Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Metastases | Completed | USA | 0 |
NCT02420821 | Phase III | Bevacizumab Sunitinib Atezolizumab | A Study of MPDL3280A (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma | Completed | USA | TUR | POL | ITA | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | AUS | 8 |
NCT02432846 | Phase II | Sunitinib | Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC) (MERECA) | Completed | USA | SWE | POL | LVA | HUN | GBR | FRA | ESP | CZE | 0 |
NCT02432963 | Phase I | MVAp53 + Pembrolizumab | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | Active, not recruiting | USA | 0 |
NCT02471846 | Phase I | Navoximod Atezolizumab | A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors | Completed | USA | FRA | ESP | 1 |
NCT02493751 | Phase I | Avelumab + Axitinib | A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer | Completed | USA | GBR | 1 |
NCT02495103 | Phase Ib/II | Metformin + Vandetanib | Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma | Terminated | USA | 0 |
NCT02498665 | Phase I | DSP-7888 | A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies | Completed | USA | 0 |
NCT02501096 | Phase Ib/II | Pembrolizumab Lenvatinib | Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | Completed | USA | NOR | ESP | 0 |
NCT02543645 | Phase Ib/II | Atezolizumab + Varlilumab | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | Terminated | USA | 0 |
NCT02559492 | Phase I | Epacadostat + Itacitinib Itacitinib + Parsaclisib | INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors | Terminated | USA | 0 |
NCT02560012 | Phase II | Everolimus Sorafenib Temsirolimus Axitinib Sunitinib Pazopanib | Personalized Targeted Inhibitors Treatment in Renal Cell Cancer | Terminated | USA | 0 |
NCT02576665 | Phase I | Toca FC + Vocimagene amiretrorepvec | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6) | Terminated | USA | 0 |
NCT02596035 | FDA approved | Nivolumab | A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374) | Completed | USA | 0 |
NCT02599779 | Phase II | Pembrolizumab | A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients | Completed | CAN | 0 |
NCT02608268 | Phase Ib/II | Spartalizumab Sabatolimab | Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | Terminated | USA | NLD | ITA | CHE | CAN | 4 |
NCT02608385 | Phase I | Pembrolizumab | Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT02619253 | Phase Ib/II | Pembrolizumab + Vorinostat | Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma | Completed | USA | 0 |
NCT02627963 | Phase III | Sorafenib Tivozanib | A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC | Completed | USA | POL | ITA | HUN | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BEL | 0 |
NCT02639182 | Phase II | AGS16F Axitinib | A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma | Completed | USA | CAN | 0 |
NCT02646319 | Phase I | Nab-rapamycin | Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations | Completed | USA | 0 |
NCT02646748 | Phase I | Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab | Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | Completed | USA | 0 |
NCT02650635 | Phase I | Cyclophosphamide + Motolimod + Pegfilgrastim | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors | Terminated | USA | 0 |
NCT02655822 | Phase I | Atezolizumab + CPI-444 CPI-444 | Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers | Completed | USA | CAN | AUS | 0 |
NCT02684006 | Phase III | Avelumab + Axitinib Sunitinib | A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101) | Completed | USA | SWE | ROU | NZL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DNK | DEU | CAN | BEL | AUT | AUS | 4 |
NCT02689167 | Phase II | Sunitinib | Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma (SURF) | Unknown status | FRA | 0 |
NCT02697591 | Phase Ib/II | INCAGN01876 | An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors | Completed | USA | 0 |
NCT02718066 | Phase Ib/II | Chidamide + Nivolumab | Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT02721732 | Phase II | Pembrolizumab | Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors | Active, not recruiting | USA | 0 |
NCT02724020 | Phase II | Sapanisertib + Serabelisib Sapanisertib Everolimus | MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma | Completed | USA | POL | ITA | GBR | FRA | ESP | CZE | CAN | 0 |
NCT02724878 | Phase II | Atezolizumab + Bevacizumab + Capecitabine | Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT02729194 | Phase I | Pazopanib | Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma | Completed | USA | 0 |
NCT02762006 | Phase I | Durvalumab + Tremelimumab | Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma | Completed | USA | 0 |
NCT02781506 | Phase II | Nivolumab | Nivolumab and Stereotactic Ablative Radiation Therapy Versus Nivolumab Alone for Metastatic Renal Cancer | Terminated | USA | 0 |
NCT02795819 | Phase I | Pazopanib + REC-2282 | Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer | Terminated | USA | 0 |
NCT02799095 | Phase I | ALKS 4230 | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | Completed | USA | POL | ESP | CAN | BEL | AUS | 1 |
NCT02811861 | Phase III | Everolimus + Lenvatinib Sunitinib Lenvatinib + Pembrolizumab | Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma | Active, not recruiting | USA | POL | NLD | ITA | ISR | IRL | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BEL | AUT | AUS | 3 |
NCT02835833 | Phase I | Bevacizumab + Nintedanib | Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors | Completed | USA | 0 |
NCT02853331 | Phase III | Axitinib + Pembrolizumab Sunitinib | Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426) | Active, not recruiting | 0 | |
NCT02853344 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427) | Completed | 0 | |
NCT02856425 | Phase I | Nintedanib + Pembrolizumab | Trial Of Pembrolizumab And Nintedanib (PEMBIB) | Recruiting | FRA | 0 |
NCT02867592 | Phase II | Cabozantinib | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | Active, not recruiting | USA | 0 |
NCT02915783 | Phase II | Everolimus + Lenvatinib | A Phase 2 Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease | Completed | USA | 0 |
NCT02923349 | Phase Ib/II | INCAGN01949 | A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors | Completed | USA | GBR | ESP | CHE | 0 |
NCT02923531 | Phase Ib/II | Nivolumab + X4P-001 | Addition of X4P-001 to Nivolumab Treatment in Patients With Renal Cell Carcinoma | Terminated | USA | 0 |
NCT02950766 | Phase I | Ipilimumab + NeoVax | A Study Combining NeoVax, a Personalized NeoAntigen Cancer Vaccine, With Ipilimumab to Treat High-risk Renal Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT02952248 | Phase I | Ezabenlimab | A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours | Completed | USA | GBR | CAN | 0 |
NCT02956798 | Phase II | Pazopanib | Pazopanib Vs. Local Therapy for Renal Cancer With Metastases | Active, not recruiting | USA | 0 |
NCT02962804 | Phase II | Nivolumab | Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC) | Withdrawn | USA | 0 |
NCT02982954 | Phase III | Ipilimumab + Nivolumab | A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer (CHECKMATE 920) | Completed | USA | 0 |
NCT02983045 | Phase Ib/II | Nivolumab + NKTR-214 | A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors (PIVOT-02) | Completed | USA | POL | ITA | GBR | FRA | ESP | CAN | BEL | 0 |
NCT02992912 | Phase II | Atezolizumab | Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours (SABR-PDL1) | Active, not recruiting | FRA | 0 |
NCT02996110 | Phase II | Nivolumab + Relatlimab Ipilimumab + Nivolumab | A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma (FRACTION-RCC) | Completed | USA | ITA | ISR | CAN | AUT | AUS | 0 |
NCT03015740 | Phase Ib/II | Nivolumab + Sitravatinib | MGCD516 Combined With Nivolumab in Renal Cell Cancer (RCC) | Completed | USA | 0 |
NCT03024437 | Phase Ib/II | Atezolizumab + Entinostat Atezolizumab + Bevacizumab + Entinostat Atezolizumab | Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma | Suspended | USA | 0 |
NCT03024996 | Phase III | Atezolizumab | A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy (IMmotion010) | Terminated | USA | TUR | POL | NLD | ITA | ISR | IRL | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 9 |
NCT03029780 | Phase II | Ipilimumab + Nivolumab | An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma | Completed | USA | AUS | 1 |
NCT03055013 | Phase III | Nivolumab | Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy (PROSPER) | Active, not recruiting | USA | ISR | CAN | 0 |
NCT03063762 | Phase I | Atezolizumab + Obinutuzumab + RO6874281 Atezolizumab + Bevacizumab + Obinutuzumab + RO6874281 | Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC) | Completed | USA | ITA | GBR | FRA | ESP | DNK | DEU | CAN | 1 |
NCT03065179 | Phase II | Ipilimumab + Nivolumab | Trial of SBRT in Combination With Nivolumab/Ipilimumab in RCC / Kidney Cancer Patients | Completed | USA | 0 |
NCT03075423 | Phase II | Sunitinib Ipilimumab + Nivolumab | Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC (SUNIFORECAST) | Active, not recruiting | NLD | GBR | FRA | ESP | DEU | CZE | BEL | 0 |
NCT03092856 | Phase II | Axitinib Axitinib + PF-04518600 | Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer | Active, not recruiting | USA | 0 |
NCT03097328 | Phase II | Sapanisertib | Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma | Completed | USA | 0 |
NCT03109015 | Phase II | Sunitinib | Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing (ASSET) | Completed | USA | 0 |
NCT03111901 | Phase Ib/II | Aldesleukin + Pembrolizumab | Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer | Withdrawn | USA | 0 |
NCT03115801 | Phase II | Atezolizumab Nivolumab | A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers | Terminated | USA | 0 |
NCT03117309 | Phase II | Ipilimumab + Nivolumab Nivolumab | Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma | Unknown status | USA | 0 |
NCT03126331 | Phase II | Nivolumab | Intermittent Nivolumab in Metastatic Renal Cell Carcinoma Patients | Completed | USA | 0 |
NCT03138512 | Phase III | Ipilimumab + Nivolumab | A Study Comparing the Combination of Nivolumab and Ipilimumab Versus Placebo in Participants With Localized Renal Cell Carcinoma (CheckMate 914) | Completed | USA | TUR | ROU | POL | NLD | ITA | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 7 |
NCT03141177 | Phase III | Cabozantinib + Ipilimumab + Nivolumab Sunitinib Cabozantinib + Nivolumab | A Study of Nivolumab Combined With Cabozantinib or Nivolumab and Ipilimumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 9ER) | Active, not recruiting | USA | TUR | ROU | POL | ITA | ISR | GRC | GBR | ESP | DEU | CZE | BRA | AUS | ARG | 4 |
NCT03142334 | Phase III | Pembrolizumab | Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564) | Active, not recruiting | USA | POL | NLD | ITA | IRL | GBR | FRA | FIN | ESP | DEU | CZE | CAN | BRA | AUS | ARG | 6 |
NCT03149822 | Phase Ib/II | Cabozantinib + Pembrolizumab | Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT03163667 | Phase II | Everolimus + Telaglenastat Everolimus | CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC | Completed | USA | 0 |
NCT03165721 | Phase II | Guadecitabine | A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer | Terminated | USA | 0 |
NCT03172754 | Phase Ib/II | Axitinib + Nivolumab | Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT03189186 | Phase I | Pembrolizumab | Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas | Withdrawn | USA | 0 |
NCT03200587 | Phase I | Avelumab + Cabozantinib | Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC) | Completed | USA | 0 |
NCT03203473 | Phase II | Nivolumab Ipilimumab + Nivolumab | Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study) | Active, not recruiting | USA | 0 |
NCT03207347 | Phase II | Niraparib | A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) | Completed | USA | 0 |
NCT03207867 | Phase II | Spartalizumab + Taminadenant | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma | Terminated | USA | NLD | ITA | FRA | ESP | DEU | CZE | CHE | BEL | AUT | AUS | ARG | 3 |
NCT03212404 | Phase I | Cosibelimab | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | Recruiting | POL | NZL | FRA | ESP | AUS | 4 |
NCT03239145 | Phase I | Pembrolizumab + Trebananib | Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor | Active, not recruiting | USA | 0 |
NCT03241173 | Phase Ib/II | INCAGN01949 + Ipilimumab INCAGN01949 + Nivolumab INCAGN01949 + Ipilimumab + Nivolumab | A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies | Completed | USA | 0 |
NCT03260504 | Phase I | Aldesleukin + Pembrolizumab | Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer | Terminated | USA | 0 |
NCT03260894 | Phase III | Epacadostat + Pembrolizumab Pazopanib + Sunitinib | Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC | Active, not recruiting | USA | TUR | NZL | NOR | ITA | IRL | HUN | GBR | FRA | ESP | DEU | CAN | BRA | AUS | 6 |
NCT03264066 | Phase II | Atezolizumab + Cabozantinib | A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors | Completed | USA | HUN | GBR | DEU | BEL | 1 |
NCT03277352 | Phase Ib/II | Epacadostat + INCAGN01876 + Pembrolizumab | INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies | Terminated | USA | 0 |
NCT03280667 | Phase II | Denosumab + Pembrolizumab | Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma (KEYPAD) | Active, not recruiting | AUS | 0 |
NCT03288532 | Phase III | Durvalumab Durvalumab + Tremelimumab | Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART) | Recruiting | GBR | 0 |
NCT03289962 | Phase I | Autogene cevumeran Atezolizumab + Autogene cevumeran | A Study of RO7198457 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors | Active, not recruiting | USA | SWE | NLD | GBR | ESP | DEU | CAN | BEL | 0 |
NCT03311334 | Phase I | Atezolizumab + DSP-7888 DSP-7888 + Nivolumab | A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Subjects With Advanced Solid Tumors | Terminated | USA | CAN | 0 |
NCT03319459 | Phase I | FATE-NK100 FATE-NK100 + Trastuzumab Cetuximab + FATE-NK100 | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | Completed | USA | 0 |
NCT03324373 | Phase II | Everolimus + Lenvatinib | Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC) | Active, not recruiting | USA | 0 |
NCT03329950 | Phase I | CDX-1140 + CDX-301 CDX-1140 | A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03396211 | Phase I | Nivolumab + Rivoceranib | Study to Evaluate Apatinib Plus Nivolumab in Patients With Unresectable or Metastatic Cancer | Completed | USA | 0 |
NCT03401788 | Phase II | Belzutifan | A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004) | Active, not recruiting | USA | GBR | FRA | DNK | 0 |
NCT03425201 | Phase Ib/II | Cabozantinib + Niraparib | Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA) (NICARAGUA) | Completed | ESP | 0 |
NCT03428217 | Phase II | Cabozantinib Cabozantinib + Telaglenastat | CB-839 With Cabozantinib vs. Placebo With Cabozantinib in Patients With Metastatic Renal Cell Carcinoma (CANTATA) | Completed | USA | NZL | ITA | GBR | FRA | ESP | DEU | AUS | 0 |
NCT03435640 | Phase Ib/II | NKTR-214 + NKTR-262 Nivolumab + NKTR-214 + NKTR-262 | A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies | Terminated | USA | 0 |
NCT03454451 | Phase I | CPI-006 CPI-006 + Pembrolizumab CPI-006 + CPI-444 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | Completed | USA | AUS | 0 |
NCT03473730 | Phase I | Daratumumab | Daratumumab in Patients With Metastatic Renal Cell Carcinoma (MRCC) or Muscle Invasive Bladder Cancer | Active, not recruiting | USA | 0 |
NCT03474497 | Phase Ib/II | Aldesleukin + Pembrolizumab + Radiotherapy | Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade | Recruiting | USA | 0 |
NCT03501381 | Phase II | Entinostat + Interleukin-12 Interleukin-12 | High Dose IL 2 and Entinostat in RCC | Active, not recruiting | USA | 0 |
NCT03502330 | Phase I | Cabiralizumab + Nivolumab + Sotigalimab Cabiralizumab + Sotigalimab | APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma | Completed | USA | 0 |
NCT03517488 | Phase I | XmAb20717 | A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) | Completed | USA | 0 |
NCT03525795 | Phase Ib/II | CPI-1205 + Ipilimumab | ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03538028 | Phase I | INCAGN02385 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | Completed | USA | 0 |
NCT03541902 | Phase II | Cabozantinib Sunitinib | Cabozantinib Versus Sunitinib for Metastatic Variant Histology Renal Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT03552380 | Phase II | Entinostat + Ipilimumab + Nivolumab | Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma | Terminated | USA | 0 |
NCT03562507 | Phase II | CEP-11981 CEP-11981 + Nivolumab | Phase 2 Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma | Terminated | USA | 0 |
NCT03592472 | Phase III | Pazopanib Abexinostat + Pazopanib | A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) | Recruiting | USA | POL | ITA | ESP | 2 |
NCT03595124 | Phase II | Nivolumab Axitinib + Nivolumab Axitinib | A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC) | Active, not recruiting | USA | 1 |
NCT03598816 | Phase II | Durvalumab + Tremelimumab | PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma | Withdrawn | 0 | |
NCT03608020 | Phase Ib/II | BMX-001 | A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy | Terminated | USA | 0 |
NCT03621982 | Phase I | Camidanlumab tesirine | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | Terminated | USA | GBR | BEL | 0 |
NCT03628677 | Phase I | AB154 AB154 + Zimberelimab | A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies | Active, not recruiting | USA | AUS | 0 |
NCT03629756 | Phase I | Etrumadenant + Zimberelimab | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | Completed | USA | AUS | 0 |
NCT03633110 | Phase Ib/II | GEN-009 GEN-009 + Nivolumab | Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | Completed | USA | 0 |
NCT03634540 | Phase II | Belzutifan + Cabozantinib | A Trial of PT2977 in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) | Active, not recruiting | USA | 0 |
NCT03635892 | Phase II | Cabozantinib + Nivolumab | A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT03637803 | Phase I | MRx0518 + Pembrolizumab | MRx0518 and Pembrolizumab Combination Study | Terminated | USA | 0 |
NCT03656718 | Phase Ib/II | Nivolumab + rHuPH20 | A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) | Active, not recruiting | USA | POL | NZL | NLD | ITA | GBR | FRA | ESP | BRA | ARG | 2 |
NCT03679767 | Phase II | Retifanlimab | A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) | Completed | USA | ROU | POL | ITA | HUN | FRA | ESP | AUT | 0 |
NCT03729245 | Phase III | Cabozantinib + Sunitinib Nivolumab + NKTR-214 | A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC) | Terminated | USA | NZL | BRA | AUS | ARG | 5 |
NCT03752398 | Phase I | Izuralimab | A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) | Completed | USA | 0 |
NCT03758781 | Phase I | Cyclophosphamide + IRX-2 + Nivolumab | IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors | Completed | USA | 0 |
NCT03775850 | Phase Ib/II | EDP1503 EDP1503 + Pembrolizumab | A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors | Completed | USA | CAN | 0 |
NCT03786796 | Phase II | Olaparib | Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations (ORCHID) | Recruiting | USA | 0 |
NCT03793166 | Phase III | Nivolumab Cabozantinib + Nivolumab Cabozantinib Ipilimumab + Nivolumab | Nivolumab and Ipilimumab Followed by Nivolumab Versus Cabozantinib and Nivolumab in Treating Patients With Metastatic Untreated Renal Cell Cancer | Active, not recruiting | USA | 1 |
NCT03798626 | Phase I | Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + XOMA 052 Paclitaxel + Ramucirumab + XOMA 052 Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + XOMA 052 Cabozantinib + XOMA 052 | Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers | Active, not recruiting | USA | ITA | ISR | GBR | ESP | DEU | CZE | CAN | BEL | AUS | 5 |
NCT03809624 | Phase II | INBRX-105 INBRX-105 + Pembrolizumab | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer (PDL1x41BB) | Terminated | USA | 0 |
NCT03816345 | Phase I | Nivolumab | Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer | Recruiting | USA | CAN | 0 |
NCT03845166 | Phase I | XL092 | A Study of XL092 in Subjects With Solid Tumors | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CZE | BEL | AUS | 0 |
NCT03849469 | Phase I | Pembrolizumab + XmAb22841 XmAb22841 | A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) | Completed | USA | 0 |
NCT03873402 | Phase III | Nivolumab Ipilimumab + Nivolumab | An Immunotherapy Study of Nivolumab Plus Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer | Active, not recruiting | USA | ROU | POL | ITA | GRC | FRA | ESP | CZE | AUT | ARG | 4 |
NCT03894618 | Phase I | SL-279252 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | Completed | USA | ESP | CAN | BEL | 0 |
NCT03905889 | Phase I | Abemaciclib + Sunitinib | A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma | Terminated | USA | 0 |
NCT03926013 | Phase I | JNJ-63898081 | A Study of JNJ-63898081 in Participants With Advanced Stage Solid Tumors | Completed | USA | CAN | 0 |
NCT03945773 | Phase II | Cabozantinib | Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors (CaboPoint) | Active, not recruiting | NLD | GBR | FRA | ESP | DEU | CHE | AUT | 0 |
NCT03961698 | Phase II | Atezolizumab + Bevacizumab + Eganelisib Atezolizumab + Eganelisib + Nab-paclitaxel | Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3) (MARIO-3) | Active, not recruiting | USA | 0 |
NCT03967522 | Phase II | Cabozantinib | Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases (CABRAMET) | Completed | FRA | 0 |
NCT03977467 | Phase II | Atezolizumab + Carboplatin Atezolizumab + Tiragolumab Atezolizumab + Cisplatin Atezolizumab + Bevacizumab + Carboplatin Atezolizumab + Bevacizumab + Cisplatin | Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor | Completed | USA | 0 |
NCT03986606 | Phase I | PSB205 | A Study of PSB205 in Subjects With Advanced Solid Tumors | Unknown status | USA | 0 |
NCT03990233 | Phase I | Effi-DEM Effi-DEM + Ezabenlimab | A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours | Active, not recruiting | FRA | BEL | 0 |
NCT03991130 | Phase II | Aldesleukin + Nivolumab | High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma | Recruiting | USA | 0 |
NCT04020185 | Phase Ib/II | IMSA101 + unspecified PD-L1 antibody IMSA101 + unspecified PD-1 antibody IMSA101 | Safety and Efficacy Study of IMSA101 in Refractory Malignancies | Completed | USA | 0 |
NCT04022343 | Phase II | Cabozantinib | Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer | Active, not recruiting | USA | 0 |
NCT04028245 | Phase I | Canakinumab + Spartalizumab | A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma (SPARC-1) | Recruiting | USA | 0 |
NCT04060407 | Phase Ib/II | CD24Fc + Ipilimumab + Nivolumab | CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI) (CINDI) | Withdrawn | USA | 0 |
NCT04068831 | Phase II | Avelumab + Talazoparib | Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma | Completed | USA | 0 |
NCT04071223 | Phase II | Cabozantinib + Radium Ra 223 dichloride Cabozantinib | Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, the RadiCaL Study | Recruiting | USA | 0 |
NCT04074967 | Phase Ib/II | Ipilimumab + Pexmetinib Nivolumab + Pexmetinib | Study of ARRY-614 Plus Either Nivolumab or Ipilimumab | Active, not recruiting | USA | 0 |
NCT04088500 | Phase II | Ipilimumab + Nivolumab | A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma | Terminated | USA | CAN | 0 |
NCT04090710 | Phase II | Nivolumab Ipilimumab + Nivolumab | SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer (CYTOSHRINK) | Active, not recruiting | CAN | AUS | 0 |
NCT04096638 | Phase I | Nivolumab + SB 11285 SB 11285 | Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT04112498 | Phase I | Nivolumab + Relatlimab + rHuPH20 | A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab | Completed | USA | 0 |
NCT04114136 | Phase II | Nivolumab Metformin + Nivolumab Pembrolizumab Metformin + Pembrolizumab Pembrolizumab + Rosiglitazone Nivolumab + Rosiglitazone | Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | Recruiting | USA | 0 |
NCT04134390 | Phase II | Cabozantinib | Study of Cabozantinib Efficacy, Safety and Tolerability in Metastatic Renal Carcinoma in Aged Fragile Patients: CABOMAYOR Study (CABOMAYOR) | Completed | ESP | 0 |
NCT04140526 | Phase Ib/II | ONC-392 ONC-392 + Pembrolizumab | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | Recruiting | USA | AUS | 0 |
NCT04198766 | Phase I | INBRX-106 INBRX-106 + Pembrolizumab | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | Recruiting | USA | 0 |
NCT04260802 | Phase Ib/II | OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | Recruiting | CAN | 0 |
NCT04262375 | Phase II | Durvalumab + Oleclumab | A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION (DOMINATION) | Withdrawn | CAN | 0 |
NCT04262427 | Phase Ib/II | Cyclophosphamide + Pembrolizumab | The CAPER Trial: A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell Carcinoma (CAPER) | Unknown status | GBR | 0 |
NCT04267120 | Phase II | Lenvatinib + Pembrolizumab | Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial) | Active, not recruiting | USA | 0 |
NCT04282018 | Phase Ib/II | BGB-10188 + Zanubrutinib BGB-10188 + Tislelizumab BGB-10188 | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | Completed | AUS | 1 |
NCT04311710 | Phase Ib/II | Ipilimumab + Nivolumab Ipilimumab + Nivolumab + rHuPH20 | A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types (CheckMate 76U) | Terminated | USA | NZL | ITA | 0 |
NCT04322955 | Phase II | Cabozantinib + Nivolumab | CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition (Cyto-KIK) | Recruiting | USA | 0 |
NCT04337970 | Phase Ib/II | Axitinib + Talazoparib | Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer | Active, not recruiting | USA | 0 |
NCT04338269 | Phase III | Cabozantinib Atezolizumab + Cabozantinib | A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment (CONTACT-03) | Active, not recruiting | USA | POL | ITA | GRC | GBR | FRA | ESP | DNK | DEU | CAN | AUS | ARG | 3 |
NCT04338685 | Phase I | RO7119929 + Tocilizumab | A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases | Completed | USA | ESP | DNK | 3 |
NCT04349267 | Phase Ib/II | BMS-986315 + Cetuximab BMS-986315 BMS-986315 + Nivolumab | Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors | Terminated | USA | CAN | 1 |
NCT04370509 | Phase II | Pembrolizumab Axitinib + Pembrolizumab | Pembrolizumab With or Without Axitinib for Treatment of Locally Advanced or Metastatic Clear Cell Kidney Cancer in Patients Undergoing Surgery | Recruiting | USA | 0 |
NCT04393350 | Phase II | Lenvatinib + Pembrolizumab | Lenvatinib and Pembrolizumab Before Surgery for the Treatment of Locally Advanced Non-Metastatic Kidney Cancer | Recruiting | USA | 0 |
NCT04413123 | Phase II | Cabozantinib + Ipilimumab + Nivolumab | Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC | Recruiting | USA | 0 |
NCT04423029 | Phase Ib/II | DF6002 DF6002 + Nivolumab | A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | FRA | ESP | AUS | 0 |
NCT04429321 | Phase I | Ipilimumab + Nivolumab | Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary | Terminated | USA | 0 |
NCT04434560 | Phase II | Ipilimumab + Nivolumab | Neoadjuvant Immunotherapy in Brain Metastases | Terminated | USA | 0 |
NCT04438083 | Phase I | CTX130 | A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma | Active, not recruiting | USA | NLD | CAN | AUS | 0 |
NCT04442126 | Phase Ib/II | NM21-1480 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | Terminated | USA | ESP | 1 |
NCT04450901 | Phase I | YBL-006 | Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors | Unknown status | AUS | 2 |
NCT04489771 | Phase II | Belzutifan | A Study of MK- 6482 in Participants With Advanced Renal Cell Carcinoma (MK-6482-013) | Active, not recruiting | USA | NLD | ISR | IRL | GRC | GBR | BEL | AUS | 1 |
NCT04495257 | Phase I | Ipilimumab + Nivolumab + Sotigalimab | A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC) | Active, not recruiting | USA | 0 |
NCT04505839 | Phase I | STP1002 | First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors | Completed | USA | 0 |
NCT04514484 | Phase I | Cabozantinib + Nivolumab | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | Active, not recruiting | USA | 0 |
NCT04521413 | Phase Ib/II | CFI-402411 + Pembrolizumab CFI-402411 | Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies | Recruiting | USA | CAN | 1 |
NCT04522323 | Phase I | Axitinib + MEDI5752 | A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma | Recruiting | USA | FRA | ESP | AUS | 0 |
NCT04540705 | Phase Ib/II | Axitinib + Nivolumab + NKTR-214 Axitinib + Nivolumab | A Study to Evaluate the Triplet Combination of Bempegaldesleukin (Bempeg/NKTR-214) Plus Nivolumab and Axitinib and the Doublet Combination of Nivolumab and Axitinib in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread (PIVOT IO 011) | Completed | USA | FRA | DEU | CAN | BRA | ARG | 2 |
NCT04572451 | Phase I | BMS-986253 + Nivolumab | Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04592653 | Phase Ib/II | ALKS 4230 ALKS 4230 + Pembrolizumab | Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) (ARTISTRY-3) | Active, not recruiting | USA | ESP | 0 |
NCT04603365 | Phase II | Pamiparib + Temozolomide | Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer | Withdrawn | 0 | |
NCT04606381 | Phase I | Amivantamab-vmjw + Lazertinib Amivantamab-vmjw + Lazertinib + rHuPH20 Amivantamab-vmjw Amivantamab-vmjw + rHuPH20 | A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies (PALOMA) | Active, not recruiting | USA | GBR | CAN | 1 |
NCT04678908 | Phase I | HB0025 | A Study of Injection HB0025 in Patients With Advanced Solid Tumors | Unknown status | USA | 1 |
NCT04691375 | Phase I | Pembrolizumab + PY314 PY314 | A Study of PY314 in Subjects With Advanced Solid Tumors | Terminated | USA | 0 |
NCT04696731 | Phase I | ALLO-647 + Cyclophosphamide + Fludarabine ALLO-316 | Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma (TRAVERSE) | Recruiting | USA | 0 |
NCT04698213 | Phase II | Avelumab + Axitinib | Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma (TIDE-A) | Unknown status | ITA | 0 |
NCT04704219 | Phase II | Lenvatinib + Pembrolizumab | Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61) (KEYNOTE-B61) | Active, not recruiting | USA | TUR | POL | ITA | IRL | HUN | GBR | FRA | ESP | CAN | AUS | 3 |
NCT04707248 | Phase I | Raludotatug deruxtecan | A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors | Recruiting | USA | 1 |
NCT04714983 | Phase I | DNX-2440 | DNX-2440 for Resectable Colorectal Liver Metastasis | Suspended | USA | 0 |
NCT04717375 | Phase Ib/II | BND-22 | Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors | Recruiting | USA | ISR | GBR | CAN | 0 |
NCT04736706 | Phase III | Lenvatinib + Pembrolizumab Lenvatinib + MK-1308A Belzutifan + Lenvatinib + Pembrolizumab | A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) | Active, not recruiting | USA | TUR | SWE | ROU | POL | NOR | ITA | IRL | HUN | HRV | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | AUS | 15 |
NCT04787042 | Phase Ib/II | Pembrolizumab + ST-067 ST-067 Obinutuzumab + ST-067 | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | Recruiting | USA | 0 |
NCT04810078 | Phase III | Nivolumab Nivolumab + rHuPH20 | A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread (CheckMate-67T) | Recruiting | USA | TUR | ROU | POL | NZL | ITA | IRL | FRA | FIN | ESP | CZE | BRA | ARG | 4 |
NCT04819373 | Phase II | BDB001 | BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors | Completed | USA | 0 |
NCT04846920 | Phase I | Belzutifan | A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018) | Active, not recruiting | USA | 0 |
NCT04902040 | Phase Ib/II | Atezolizumab + Avelumab + Durvalumab + Nivolumab + Pembrolizumab + Plinabulin Atezolizumab + Avelumab + Durvalumab + Nivolumab + Pembrolizumab | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | Active, not recruiting | USA | 0 |
NCT04904302 | Phase II | Nivolumab + Sitravatinib | Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer | Active, not recruiting | USA | 0 |
NCT04913025 | Phase II | Pembrolizumab Nivolumab | REduced Frequency ImmuNE Checkpoint Inhibition in Cancers (REFINE) | Recruiting | GBR | 0 |
NCT04955743 | Phase II | Lenvatinib + Pembrolizumab | Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma | Recruiting | USA | 0 |
NCT04969315 | Phase Ib/II | TT-10 | TT-10 as a Single Agent in Subjects With Advanced Selected Solid Tumors | Active, not recruiting | USA | 0 |
NCT04972981 | Phase I | ADCT-901 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors | Active, not recruiting | USA | GBR | ESP | 0 |
NCT04981509 | Phase II | Atezolizumab + Bevacizumab + Erlotinib | Testing of Bevacizumab, Erlotinib, and Atezolizumab for Advanced-Stage Kidney Cancer | Recruiting | USA | 0 |
NCT04987203 | Phase III | Nivolumab + Tivozanib Tivozanib | Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma | Active, not recruiting | USA | POL | ITA | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 3 |
NCT04991740 | Phase I | JNJ-78306358 | A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors | Completed | ISR | ESP | 0 |
NCT05012371 | Phase II | Cabozantinib Everolimus + Lenvatinib | Lenvatinib With Everolimus Versus Cabozantinib for Second-Line Treatment of Metastatic Renal Cell Cancer | Active, not recruiting | USA | 0 |
NCT05024318 | Phase II | Pembrolizumab | NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma (NAPSTER) | Recruiting | AUS | 0 |
NCT05029882 | Phase I | ABBV-400 + Bevacizumab ABBV-400 Bevacizumab + Trifluridine-tipiracil hydrochloride | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab | Recruiting | USA | POL | ISR | FRA | ESP | AUS | 4 |
NCT05048212 | Phase II | Cabozantinib + Ipilimumab + Nivolumab | A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases | Recruiting | USA | 0 |
NCT05052268 | Phase Ib/II | XTX202 | XTX202 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT05061537 | Phase I | PF-06801591 + PF-07263689 PF-07263689 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | Terminated | USA | 0 |
NCT05069935 | Phase I | Atezolizumab + FT538 Cetuximab + FT538 FT538 + Trastuzumab FT538 + Pembrolizumab FT538 + Nivolumab Avelumab + FT538 Cyclophosphamide + Fludarabine | FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | Terminated | USA | 0 |
NCT05092373 | Phase I | Cabozantinib Atezolizumab + Nab-paclitaxel | Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax | Recruiting | USA | 0 |
NCT05101070 | Phase Ib/II | Pembrolizumab + S-531011 Pembrolizumab S-531011 | S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors (aCCeleR8-001) | Recruiting | USA | 1 |
NCT05114668 | Phase I | EVT801 | Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours | Active, not recruiting | FRA | 0 |
NCT05118841 | Phase I | ZX-4081 | Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors | Unknown status | USA | 0 |
NCT05122546 | Phase I | Cabozantinib + Nivolumab Cabozantinib + CBM588 + Nivolumab | CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer | Active, not recruiting | USA | 0 |
NCT05155033 | Phase II | Aldesleukin + Pembrolizumab | Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma | Recruiting | USA | 0 |
NCT05176288 | Phase II | Avelumab + Axitinib + Palbociclib | Avelumab, Palbociclib and Axitinib in Advanced RCC (APART) | Withdrawn | 0 | |
NCT05176483 | Phase I | Nivolumab + NKTR-214 XL092 Nivolumab + NKTR-214 + XL092 Ipilimumab + Nivolumab + XL092 Nivolumab + XL092 Ipilimumab + Nivolumab | Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors (STELLAR-002) | Recruiting | USA | POL | NZL | ITA | ISR | GBR | FRA | ESP | DEU | CHE | BEL | AUT | AUS | 0 |
NCT05188118 | Phase I | Cabozantinib Nivolumab Everolimus Ipilimumab Lenvatinib | Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma | Recruiting | USA | 0 |
NCT05200559 | Phase Ib/II | E7777 + Pembrolizumab | T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05229601 | Phase I | HFB301001 | A Study of HFB301001 in Adult Patients With Advanced Solid Tumors | Active, not recruiting | USA | ESP | 0 |
NCT05238883 | Phase I | HFB200301 HFB200301 + Tislelizumab | A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | Recruiting | USA | ESP | 0 |
NCT05239533 | Phase II | 177Lu-girentuximab + Nivolumab | Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer | Recruiting | USA | 0 |
NCT05239728 | Phase III | Pembrolizumab Belzutifan + Pembrolizumab | A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022) | Active, not recruiting | USA | TUR | SWE | ROU | POL | NZL | NLD | ITA | ISR | IRL | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CAN | BRA | BGR | AUS | 10 |
NCT05241561 | Phase II | Cabozantinib | Cabo-POLARIS : A Trial to Evaluate Cabozantinib Among Haemodialysied Patients (Cabo-POLARIS) | Not yet recruiting | FRA | 0 |
NCT05259319 | Phase I | Atezolizumab + Tiragolumab | Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT) (IMMUNOs-SBRT) | Recruiting | FRA | 0 |
NCT05263050 | Phase II | Cabozantinib | Phase II Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma | Recruiting | USA | 0 |
NCT05263180 | Phase I | EMB-09 | A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors. | Recruiting | AUS | 1 |
NCT05269381 | Phase I | Cyclophosphamide + Neoantigen peptide vaccine + Pembrolizumab + Sargramostim | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (PNeoVCA) | Recruiting | USA | 0 |
NCT05293496 | Phase I | MGC018 + MGD019 | A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT05298592 | Phase I | BMS-986406 + Nivolumab BMS-986406 | A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors | Completed | USA | ESP | BEL | ARG | 2 |
NCT05319015 | Phase II | Lenvatinib + Pembrolizumab | Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus | Recruiting | USA | 0 |
NCT05323045 | Phase I | BYON3521 | A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521 | Active, not recruiting | NLD | ITA | GBR | BEL | 0 |
NCT05327686 | Phase II | Axitinib + Pembrolizumab Lenvatinib + Pembrolizumab Ipilimumab + Nivolumab Avelumab + Axitinib Cabozantinib + Nivolumab | Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study (SAMURAI) | Recruiting | USA | 0 |
NCT05329532 | Phase Ib/II | Modi-1 Modi-1 + Pembrolizumab | Modi-1 in Breast, Head and Neck, Ovarian, or Renal Cancer (ModiFY) | Recruiting | GBR | 0 |
NCT05354323 | Phase I | NECVAX-NEO1 | NECVAX-NEO1 in Addition to Checkpoint Inhibitor in Patients With Solid Tumors | Recruiting | LTU | 0 |
NCT05361720 | Phase II | Cabozantinib + Nivolumab Ipilimumab + Nivolumab | Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study | Recruiting | USA | 0 |
NCT05411081 | Phase II | Cabozantinib Atezolizumab + Cabozantinib | Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial | Recruiting | USA | 0 |
NCT05417321 | Phase Ib/II | HB0036 | A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT05462873 | Phase I | QEQ278 | A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | ITA | FRA | ESP | DEU | BEL | 3 |
NCT05468697 | Phase Ib/II | Belzutifan + Palbociclib Belzutifan | A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024) | Recruiting | USA | ISR | AUS | 0 |
NCT05479812 | Phase I | WTX-124 Pembrolizumab + WTX-124 | Dose Escalation Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05496595 | Phase I | DCBY02 | DCBY02 or DCSZ11 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors | Terminated | USA | 0 |
NCT05585034 | Phase I | Pembrolizumab + XmAb808 | Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb808 in Combination With Pembrolizumab in Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05597839 | Phase Ib/II | DF9001 DF9001 + Nivolumab | Study of DF9001 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05625412 | Phase I | CC-90001 + Nivolumab Capecitabine + CC-90001 CC-90001 CC-90001 + Docetaxel | A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors | Recruiting | USA | ITA | FRA | ESP | CAN | AUS | ARG | 2 |
NCT05641545 | Phase I | IVAC | IVAC-RCC-001: A Personalized Neoantigen Vaccine as Add-on to Standard of Care Checkpoint Inhibitor in Advanced/Metastatic RCC Patients | Terminated | DEU | 0 |
NCT05678673 | Phase III | Nivolumab + XL092 Sunitinib | Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (STELLAR-304) | Recruiting | USA | POL | NLD | ITA | FRA | FIN | ESP | DEU | CZE | BRA | AUS | ARG | 4 |
NCT05703854 | Phase Ib/II | CAR.70/IL15-transduced CB-NK cells Cyclophosphamide + Fludarabine | Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma | Recruiting | USA | 0 |
NCT05714553 | Phase Ib/II | Docetaxel + Leucovorin + NUC-3373 Leucovorin + NUC-3373 + Pembrolizumab | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | Recruiting | GBR | 0 |
NCT05721222 | Phase Ib/II | PRO1160 | PRO1160 for Advance Solid and Liquid Tumors (PRO1160-001) | Recruiting | USA | 1 |
NCT05733715 | Phase I | Pembrolizumab Lenvatinib + Pembrolizumab | Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma | Recruiting | USA | 0 |
NCT05759923 | Phase I | OATD-02 | First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours | Recruiting | POL | 0 |
NCT05783622 | Phase I | JANX008 | Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies | Recruiting | USA | 0 |
NCT05785754 | Phase I | DCSZ11 | DCSZ11 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors | Recruiting | USA | AUS | 2 |
NCT05789069 | Phase I | HFB200603 HFB200603 + Tislelizumab | A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | Recruiting | USA | ITA | ESP | 0 |
NCT05817903 | Phase II | Nivolumab Axitinib + Nivolumab | Phase II Study of Axitinib Intensification Plus Nivolumab Compared to Nivolumab Alone After Induction With Nivolumab Plus Ipilimumab in mRCC Patients Without Previous CR (AxIn) | Recruiting | ITA | 0 |
NCT05826600 | Phase I | OMX-0407 | A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically | Recruiting | ESP | BEL | 0 |
NCT05836324 | Phase I | INCA33890 | A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | Recruiting | USA | ITA | GBR | FRA | ESP | DNK | CHE | 1 |
NCT05846646 | Phase II | Pembrolizumab Nivolumab IMSA101 + Nivolumab IMSA101 + Pembrolizumab | Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC | Terminated | USA | 0 |
NCT05891171 | Phase I | AB598 + Carboplatin + Pemetrexed Disodium + Zimberelimab AB598 AB598 + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers (ARC-25) | Recruiting | USA | AUS | 0 |
NCT05904496 | Phase I | BGB-30813 BGB-30813 + Tislelizumab | A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | ESP | AUS | 0 |
NCT05920408 | Phase Ib/II | EXS21546 | Study to Assess EXS21546 in Combination in Patients With Advanced Solid Tumours | Terminated | FRA | BEL | 0 |
NCT05928806 | Phase II | Balstilimab + Botensilimab Ipilimumab + Nivolumab | Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial (ARCITECT) | Recruiting | USA | 0 |
NCT05931393 | Phase II | Cabozantinib + Nivolumab Cabozantinib | Sequential Treatment of Cabozantinib or Cabozantinib With Nivolumab for Advanced Renal Cell Carcinoma (RCC) | Recruiting | USA | 0 |
NCT05934539 | Phase Ib/II | ALG.APV-527 | ALG.APV-527 First-in-human Study | Recruiting | USA | 0 |
NCT05947474 | Phase I | ORB-011 | ORB-011 In Patients With Advanced Solid Tumors (ORB) | Recruiting | USA | 0 |
NCT05949424 | FDA approved | Lenvatinib Olaparib Pazopanib Palbociclib Sunitinib | OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults (OPTI-DOSE) | Not yet recruiting | NLD | 0 |
NCT05958199 | Phase I | NPX267 | Treatment With NPX267 for Subjects With Solid Tumors Known to Express HHLA-2 | Recruiting | USA | 0 |
NCT06004336 | Phase II | Pembrolizumab | A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs) | Recruiting | USA | 0 |
NCT06005818 | Phase II | Pembrolizumab | Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC) (MRD GATE RCC) | Recruiting | USA | 0 |
NCT06026410 | Phase I | Cabozantinib + KO-2806 Adagrasib + KO-2806 KO-2806 | KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors (FIT-001) | Recruiting | USA | 0 |
NCT06034860 | Phase I | MT-8421 + Nivolumab MT-8421 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types | Terminated | USA | 0 |
NCT06047379 | Phase Ib/II | NEO212 NEO212 + Regorafenib Carboplatin + NEO212 + Paclitaxel Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NEO212 Ipilimumab + NEO212 NEO212 + Pembrolizumab NEO212 + Nivolumab | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | Recruiting | USA | 0 |
NCT06049576 | Phase I | Camu camu + Ipilimumab + Nivolumab Ipilimumab + Nivolumab | Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma | Suspended | USA | 0 |
NCT06053658 | Phase II | Nivolumab + Tivozanib | Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma | Recruiting | USA | 0 |
NCT06099782 | Phase II | MK-3475A Pembrolizumab | A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) | Active, not recruiting | USA | TUR | POL | NZL | FRA | AUS | ARG | 3 |
NCT06108050 | Phase I | JZP898 + Pembrolizumab JZP898 | JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT06108479 | Phase I | DF6215 | Study of DF6215 in Patients With Advanced Solid Tumors | Recruiting | USA | FRA | AUS | 0 |
NCT06120075 | Phase I | AB801 AB801 + Docetaxel AB801 + Docetaxel + Zimberelimab | A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies (ARC-27) | Recruiting | USA | 0 |
NCT06132945 | Phase I | Cabozantinib + Nivolumab | A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain | Recruiting | USA | 0 |
NCT06234605 | Phase I | HC-7366 Belzutifan + HC-7366 | A Study of HC-7366 in Combination With Belzutifan (WELIRE) in Patients With Renal Cell Carcinoma | Recruiting | USA | 0 |
NCT06240728 | Phase I | NPX887 | A Study of NPX887 for Participants With Solid Tumors Known to Express HHLA2/B7-H7 | Recruiting | USA | 0 |
NCT06274437 | Phase I | BND-35 + Cetuximab BND-35 + Nivolumab BND-35 | A Study of BND-35 in Participants With Advanced Solid Tumors | Recruiting | ISR | 0 |
NCT06284564 | Phase II | Evolocumab + Nivolumab | A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC) | Recruiting | USA | 0 |
NCT06302569 | Phase II | Enfortumab vedotin-ejfv + Pembrolizumab | Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma (REPRINT) | Not yet recruiting | ITA | 0 |
NCT06307431 | Phase II | Pembrolizumab mRNA-4157 + Pembrolizumab | A Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma (V940-004) | Recruiting | USA | TUR | POL | ITA | GBR | FRA | ESP | DEU | CAN | AUS | ARG | 3 |
NCT06332755 | Phase I | LB-LR1109 | Study to Evaluate LB-LR1109 for the Treatment of Solid Tumors (LB-LR1109) | Recruiting | USA | 0 |
NCT06362369 | Phase Ib/II | 7HP349 + Ipilimumab + Nivolumab | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | Recruiting | USA | 0 |
NCT06364631 | Phase III | Cabozantinib + Nivolumab Ipilimumab + Nivolumab Axitinib + Pembrolizumab Lenvatinib + Pembrolizumab | CARE1 Pragmatic Clinical Trial (CARE1) | Recruiting | FRA | 0 |
NCT06399419 | Phase I | CBM588 + Ipilimumab + Nivolumab | CBM588 in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer | Recruiting | USA | 0 |
NCT06444815 | Phase I | VET3-TGI Pembrolizumab + VET3-TGI | A Study of VET3-TGI in Patients With Solid Tumors (STEALTH-001) | Recruiting | USA | 0 |
NCT06514651 | Phase I | MAQ-001 Ipilimumab + MAQ-001 | MAQ-001 in Patients With Advanced Solid Tumors | Recruiting | FRA | 0 |
NCT06546553 | Phase I | PF-07826390 PF-06801591 + PF-07826390 | A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines. | Recruiting | USA | 0 |
NCT06580938 | Phase I | PF-07921585 PF-06801591 + PF-07921585 | A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer | Recruiting | USA | 0 |
NCT06582017 | Phase I | QXL138AM | Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma | Recruiting | USA | 0 |
NCT06626256 | Phase I | Cyclophosphamide + Fludarabine Aldesleukin + STIL101 | STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma | Not yet recruiting | USA | 0 |
NCT06634849 | Phase Ib/II | PTT-4256 | An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours. | Recruiting | AUS | 0 |
NCT06708949 | Phase II | Ipilimumab + Nivolumab Ipilimumab + Nivolumab and relatlimab-rmbw | A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC) | Not yet recruiting | USA | 0 |